FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308394513> ?p ?o ?g. }

• W4308394513 abstract "<h3>Background</h3> SGN-B7H4V is an investigational vedotin antibody-drug conjugate (ADC) directed to B7-H4, an immune checkpoint ligand with elevated expression on multiple solid tumor types, including breast, ovarian, and endometrial tumors.¹ SGN-B7H4V is composed of an anti-B7-H4 human monoclonal antibody conjugated to the microtubule disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable peptide linker. This vedotin drug linker system has been clinically validated in multiple ADC programs, including brentuximab vedotin, enfortumab vedotin, and tisotumab vedotin. SGN-B7H4V is designed to bind the immune checkpoint ligand B7-H4, internalize the ligand/ADC complex from the surface of B7-H4-expressing tumor cells and release the cytotoxic payload, MMAE, within the cell. SGN-B7H4V demonstrates strong antitumor activity in preclinical models through multiple potential mechanisms including direct MMAE-mediated cytotoxicity as well as antibody-mediated functions including antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) in vitro.¹ Vedotin ADCs can elicit MMAE-mediated immunomodulatory changes to the tumor microenvironment (TME) via induction of immunogenic cell death ^2–4 which may position vedotin ADCs to uniquely synergize with checkpoint inhibitors. This is supported by clinically meaningful responses observed when vedotin ADCs are paired with anti-PD1 agents.^5,6 Here, we use an immunocompetent mouse model to characterize SGN-B7H4V-mediated immunomodulatory activity along with antitumor activity and induction of immune memory in combination with an anti-PD1 agent. <h3>Methods</h3> Immunomodulatory changes in SGN-B7H4V-treated tumors were characterized by RNAseq and immunohistochemistry. The antitumor activity of SGN-B7H4V as a monotherapy and in combination with an anti-PD1 agent was evaluated using a murine B7-H4-expressing Renca syngeneic tumor model. Finally, tumor rechallenge experiments were performed to evaluate immune memory. <h3>Results</h3> Treatment of B7-H4-expressing syngeneic tumors with SGN-B7H4V led to immunomodulatory changes in the TME, including recruitment of multiple immune cell types and upregulation of immune-related genes that have been previously associated with response to anti-PD(L)1 agents. Moreover, SGN-B7H4V drove robust antitumor activity as well as durable immune memory as a monotherapy and in combination with an anti-PD1 agent. <h3>Conclusions</h3> In preclinical models, SGN-B7H4V demonstrates robust antitumor activity accompanied by immunomodulatory changes in the TME. Moreover, SGN-B7H4V in combination with an anti-PD1 agent led to improved antitumor activity and elicited durable immune memory. Altogether, these nonclinical data further support the evaluation of SGN-B7H4V as a monotherapy in the ongoing Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors (NCT05194072) and potential future clinical combinations with immunotherapies. <h3>References</h3> Gray E, <i>et al</i>. 854 SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models.<i> Journal for ImmunoTherapy of Cancer</i> 2021;<b>9</b>:A895–A895. Pusztai LL, Hale H, Grosse-Wilde C, Specht A, Modi J, Han S, Cortes H, Oliveira J, Garfin H, Wang P, Onsum ZM. Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients. <i>Journal for ImmunoTherapy of Cancer</i> 2020;<b>8</b>. Liu BAOD, Snead K, Gosink J, Tenn E-T, Zaval M, Cao A, Sahetya D, Nesterova A, Hensley K, Cochran J, Gardai S, Lewis TS. Enfortumab vedotin, an anti-Nectin-4 ADC demonstrates bystander cell killing and immunogenic cell death anti-tumor activity mechanisms of action in urothelial cancers. <i>Cancer Research</i>, 2020;<b>80</b>(16_Supplement):5581. Gray EHK, Allred S, Trueblood E, Gosink J, Thurman R, Smith K, Jacquemont C, Bieda M; Gow J, Harris J, Brady L, Soumaoro I, Jain S, Nicacio L, Gardai S. Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death. <i>Journal for ImmunoTherapy of Cancer</i> 2020;<b>8</b>. Rosenberg JEF, Friedlander TW; Milowsky MI, Srinivas S, Petrylak DP, Merchan JR, Bilen MA, Carret A-S, Yuan N, Sasse C, Hoimes CJ. Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. <i>Journal of Clinical Oncology</i> 2020;<b>38</b>(6):441–441. Advani RH, <i>et al</i>. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. <i>Blood</i> 2021;<b>138</b>(6):427–438. <h3>Ethics Approval</h3> All animal studies were conducted in accordance with protocols reviewed and approved by the Institutional Animal Care and Use Committee at Seagen or the external testing facility that conducted the studies." @default.
• W4308394513 created "2022-11-11" @default.
• W4308394513 creator A5006771343 @default.
• W4308394513 creator A5017378932 @default.
• W4308394513 creator A5019036090 @default.
• W4308394513 creator A5023894574 @default.
• W4308394513 creator A5029132704 @default.
• W4308394513 creator A5040672854 @default.
• W4308394513 creator A5053597932 @default.
• W4308394513 creator A5065579271 @default.
• W4308394513 creator A5068006242 @default.
• W4308394513 creator A5076787926 @default.
• W4308394513 creator A5078996982 @default.
• W4308394513 creator A5079575989 @default.
• W4308394513 creator A5086343549 @default.
• W4308394513 creator A5087092965 @default.
• W4308394513 date "2022-11-01" @default.
• W4308394513 modified "2023-10-04" @default.
• W4308394513 title "1190 SGN-B7H4V induces immunomodulatory changes to the tumor microenvironment and pairs well with an anti-PD1 agent in a preclinical model" @default.
• W4308394513 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1190" @default.
• W4308394513 hasPublicationYear "2022" @default.
• W4308394513 type Work @default.
• W4308394513 citedByCount "0" @default.
• W4308394513 crossrefType "proceedings-article" @default.
• W4308394513 hasAuthorship W4308394513A5006771343 @default.
• W4308394513 hasAuthorship W4308394513A5017378932 @default.
• W4308394513 hasAuthorship W4308394513A5019036090 @default.
• W4308394513 hasAuthorship W4308394513A5023894574 @default.
• W4308394513 hasAuthorship W4308394513A5029132704 @default.
• W4308394513 hasAuthorship W4308394513A5040672854 @default.
• W4308394513 hasAuthorship W4308394513A5053597932 @default.
• W4308394513 hasAuthorship W4308394513A5065579271 @default.
• W4308394513 hasAuthorship W4308394513A5068006242 @default.
• W4308394513 hasAuthorship W4308394513A5076787926 @default.
• W4308394513 hasAuthorship W4308394513A5078996982 @default.
• W4308394513 hasAuthorship W4308394513A5079575989 @default.
• W4308394513 hasAuthorship W4308394513A5086343549 @default.
• W4308394513 hasAuthorship W4308394513A5087092965 @default.
• W4308394513 hasBestOaLocation W43083945131 @default.
• W4308394513 hasConcept C109316439 @default.
• W4308394513 hasConcept C159654299 @default.
• W4308394513 hasConcept C185592680 @default.
• W4308394513 hasConcept C202751555 @default.
• W4308394513 hasConcept C203014093 @default.
• W4308394513 hasConcept C2776107976 @default.
• W4308394513 hasConcept C2777325958 @default.
• W4308394513 hasConcept C2778191690 @default.
• W4308394513 hasConcept C3020616263 @default.
• W4308394513 hasConcept C40677261 @default.
• W4308394513 hasConcept C502942594 @default.
• W4308394513 hasConcept C542903549 @default.
• W4308394513 hasConcept C55493867 @default.
• W4308394513 hasConcept C70905583 @default.
• W4308394513 hasConcept C71924100 @default.
• W4308394513 hasConcept C98274493 @default.
• W4308394513 hasConceptScore W4308394513C109316439 @default.
• W4308394513 hasConceptScore W4308394513C159654299 @default.
• W4308394513 hasConceptScore W4308394513C185592680 @default.
• W4308394513 hasConceptScore W4308394513C202751555 @default.
• W4308394513 hasConceptScore W4308394513C203014093 @default.
• W4308394513 hasConceptScore W4308394513C2776107976 @default.
• W4308394513 hasConceptScore W4308394513C2777325958 @default.
• W4308394513 hasConceptScore W4308394513C2778191690 @default.
• W4308394513 hasConceptScore W4308394513C3020616263 @default.
• W4308394513 hasConceptScore W4308394513C40677261 @default.
• W4308394513 hasConceptScore W4308394513C502942594 @default.
• W4308394513 hasConceptScore W4308394513C542903549 @default.
• W4308394513 hasConceptScore W4308394513C55493867 @default.
• W4308394513 hasConceptScore W4308394513C70905583 @default.
• W4308394513 hasConceptScore W4308394513C71924100 @default.
• W4308394513 hasConceptScore W4308394513C98274493 @default.
• W4308394513 hasLocation W43083945131 @default.
• W4308394513 hasOpenAccess W4308394513 @default.
• W4308394513 hasPrimaryLocation W43083945131 @default.
• W4308394513 hasRelatedWork W1967470546 @default.
• W4308394513 hasRelatedWork W1997275703 @default.
• W4308394513 hasRelatedWork W2061223989 @default.
• W4308394513 hasRelatedWork W2067077431 @default.
• W4308394513 hasRelatedWork W2078069482 @default.
• W4308394513 hasRelatedWork W2094936714 @default.
• W4308394513 hasRelatedWork W2365193933 @default.
• W4308394513 hasRelatedWork W2417631503 @default.
• W4308394513 hasRelatedWork W2443772760 @default.
• W4308394513 hasRelatedWork W2737440291 @default.
• W4308394513 isParatext "false" @default.
• W4308394513 isRetracted "false" @default.
• W4308394513 workType "article" @default.